Advertisements


Roche says entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2019

Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 21st, 2018

Genentech says entrectinib shrank tumors in Phase I/II study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 15th, 2019

Roche says $4.3 billion Spark offer still on track for June completion

Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it......»»

Category: topSource: reutersApr 3rd, 2019

Roche extends Spark offer after getting only 29 percent

Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 percent of Spark's shares in a tender originally due to end on Wednesday......»»

Category: topSource: reutersApr 3rd, 2019

Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?

Roche and Biogen are spending big bucks on gene therapy biotech stocks......»»

Category: topSource: foxnewsMar 8th, 2019

Roche takes on Loxo, Bayer in gene-defined cancer class - Reuters

ReutersRoche takes on Loxo, Bayer in gene-defined cancer classReutersMUNICH (Reuters) - Roche'.....»»

Category: topSource: googlenewsOct 21st, 2018

Roche"s (RHHBY) BLA for Lymphoma Drug Gets Priority Review

The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, an.....»»

Category: dealsSource: nytFeb 19th, 2019

Roche bids $4.8B for Spark and its gene therapy

Roche Holding AG will buy Spark Therapeutics Inc. for $4.8 billion, a deal that will give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes......»»

Category: topSource: moneycentralFeb 25th, 2019

Roche Bids $4.3 Billion for U.S.-Based Gene Therapy Specialist Spark

Purchasing Philadelphia-based Spark will help Roche to compete with Basel-based neighbor Novartis AG in developing the new area of medicine .....»»

Category: europeSource: fortuneFeb 25th, 2019

Roche may spark another bull run for gene therapy names, says Credit Suisse

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 25th, 2019

Roche Bids $4.8 Billion for U.S.-Based Gene Therapy Specialist Spark

Purchasing Philadelphia-based Spark will help Roche to compete with Basel-based neighbor Novartis AG in developing the new area of medicine .....»»

Category: europeSource: fortuneFeb 25th, 2019

Roche bets $4.3 billionon Spark in gene therapy move

Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. Ciara Lee reports......»»

Category: topSource: moneycentralFeb 25th, 2019

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: Latest Ratings fo.....»»

Category: blogSource: benzingaFeb 25th, 2019

Here"s Why Gene Therapy Stocks Are Soaring Today

Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring......»»

Category: topSource: foxnewsFeb 25th, 2019

Brainstorm Health: Roche Spark Therapeutics Deal, GE Health Spinoff, Amgen Court Victory

Brainstorm Health Daily: February 25, 2019 Happy Monday, readers! I hope you enjoyed your weekend. Oh, what a difference a deal (or two) can make. Biotech companies developing gene therapies and gene editing tech saw their shares.....»»

Category: europeSource: fortuneFeb 25th, 2019

Roche Pays Up To Enter The Gene Therapy Space

Roche Pays Up To Enter The Gene Therapy Space.....»»

Category: topSource: seekingalphaFeb 26th, 2019

Gene-edited seed developer Cibus officially withdraws $100 million IPO

Cibus which is develop.....»»

Category: futuresSource: nasdaq11 hr. 3 min. ago

Novartis gets approval for world"s costliest drug

Swiss drugmaker Novartis received U.S. approval to sell a gene therapy for $2.125 million per single dose, making it the world's most expensive drug......»»

Category: videoSource: reuters20 hr. 48 min. ago

The FDA approves gene therapy that is the most expensive drug in the world

Drug firm Novartis’s Zolgensma, a $2.1 million one-time gene therapy, treats infants with spinal muscular atrophy......»»

Category: topSource: washpost21 hr. 33 min. ago

The FDA approves a gene therapy that is the most expensive drug in the world

The gene therapy Zolgensma, priced at $2.1 million, treats infants with spinal muscular atrophy......»»

Category: topSource: washpostMay 24th, 2019